|
BRPI0705943A2
|
|
oral dosage formulations of protease resistant polypeptides and their uses for treatment
|
|
KR20080094312A
|
|
Oral dosage formulations of protease-resistant polypeptides and uses thereof for treatment
|
|
MX2007004822A
|
|
Oral dosage formulations of protease-resistant polypeptides.
|
|
CA2583716A1
|
|
Oral dosage formulations of protease resistant polypeptides
|
|
AU2007201663A1
|
|
Oral dosage formulations of protease resistant polypeptides
|
|
EP1877434A2
|
|
Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
|
|
AU2003267700A1
|
|
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
AU2003263552A1
|
|
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
|
EP1427823A2
|
|
High throughput directed evolution by rational mutagenesis
|
|
AU2002328128A1
|
|
Mutant recombinant adeno-associated viruses related applications
|
|
WO0144809A2
|
|
Evaluation of biological agents in living target cells
|
|
FR2808804A1
|
|
Method for determining the title of biological agents in real time in living target cells and its applications
|
